← back to search

Martina Seiffert

Rigshospitalet · DE
Area of research
Genetics · Immunology
Research interest
Research interests include Chronic Lymphocytic Leukemia Research, Immune Cell Function and Interaction, CAR-T cell therapy research, and Lymphoma Diagnosis and Treatment.
h-index
40
citations
5,499
works
163
NIH funding
primary concept
Biology
email

Recent publications

Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target
Nature Communications 2025cited by 10position: lastdoi
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL
Nature Communications 2025cited by 5position: lastdoi
198 | CD3xCD20 BISPECIFIC EPCORITAMAB INDUCES ANTITUMOR ACTIVITY AND FAVORABLE T‐CELL DYNAMICS OVER TIME WITH PROLONGED THERAPY
Hematological Oncology 2025cited by 1position: middledoi
Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities
Nature Cell Biology 2024cited by 62position: middledoi
CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models
Blood 2024cited by 15position: middledoi
The diversity of the microbiome impacts chronic lymphocytic leukemia development in mice and humans
Haematologica 2024cited by 12position: middledoi
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia
Blood 2024cited by 7position: lastdoi
Lessons learned from the Eµ-TCL1 mouse model of CLL
Seminars in Hematology 2024cited by 5position: lastdoi
Sphingosine-1-Phosphate Recruits Macrophages and Microglia and Induces a Pro-Tumorigenic Phenotype That Favors Glioma Progression
Cancers 2023cited by 16position: lastdoi
Interleukin-27 potentiates CD8+ T-cell-mediated antitumor immunity in chronic lymphocytic leukemia
Haematologica 2023cited by 16position: middledoi
Simultaneous Inhibition of PI3Kgamma and PI3Kdelta Deteriorates T-cell Function With Implications for Chronic Lymphocytic Leukemia
HemaSphere 2023cited by 11position: middledoi
scSNPdemux: a sensitive demultiplexing pipeline using single nucleotide polymorphisms for improved pooled single-cell RNA sequencing analysis
BMC Bioinformatics 2023cited by 6position: middledoi
TIGIT: an immune checkpoint beyond T cells in chronic lymphocytic leukemia
Haematologica 2023cited by 3position: firstdoi
Multi-layered chromatin proteomics identifies cell vulnerabilities in DNA repair
Nucleic Acids Research 2022cited by 14position: middledoi
Multimodal and spatially resolved profiling identifies distinct patterns of T-cell infiltration in nodal B-cell lymphoma entities
bioRxiv (Cold Spring Harbor Laboratory) 2022cited by 11position: middledoi
High-dimensional single-cell definition of CLL T cells identifies Galectin-9 as novel immunotherapy target
bioRxiv (Cold Spring Harbor Laboratory) 2022cited by 6position: lastdoi
Single-Cell Omics Analyses Identify the TIM-3 Ligand Galectin-9 As Novel Immunotherapy Target for Chronic Lymphocytic Leukemia
Blood 2022cited by 2position: lastdoi
Editorial: New Insights into the Complexity of Tumor Immunology in B-cell Malignancies: Tumor Immunology and Immunotherapy
Frontiers in Oncology 2022cited by 1position: firstdoi
Editorial: New Insights Into the Complexity of Tumor Immunology in B-Cell Malignancies: Prognostic and Predictive Biomarkers and Therapy
Frontiers in Oncology 2022cited by 0position: middledoi
Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity
Immunity 2021cited by 127position: lastdoi
EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia
Leukemia 2021cited by 54position: lastdoi
EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia
Leukemia 2021cited by 47position: lastdoi
TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target
Blood 2021cited by 30position: middledoi
Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia
Blood 2021cited by 28position: middledoi
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Frontiers in Immunology 2021cited by 25position: middledoi
Proteomic and bioinformatic profiling of neutrophils in CLL reveals functional defects that predispose to bacterial infections
Blood Advances 2021cited by 24position: middledoi
An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies
Blood Advances 2021cited by 16position: middledoi
Increased B‐cell activity with consumption of activated monocytes in severe COVID‐19 patients
European Journal of Immunology 2021cited by 14position: middledoi
Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
Haematologica 2021cited by 13position: middledoi
IDO1-Targeted Therapy Does Not Control Disease Development in the Eµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
Cancers 2021cited by 12position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Peter Lichter · German Cancer Research Center42 papers (2012–2023)Stephan Stilgenbauer · Spital STS33 papers (2012–2023)Bola S. Hanna · Harvard University24 papers (2013–2021)Philipp M. Roessner · Boehringer Ingelheim (Germany)23 papers (2017–2024)Thorsten Zenz · Monash University16 papers (2012–2021)Sascha Dietrich · Research Institute of Radiology16 papers (2013–2024)Selcen Öztürk · Heidelberg University15 papers (2017–2024)Laura Llaó Cid · Consorci Institut D'Investigacions Biomediques August Pi I Sunyer14 papers (2016–2024)Marc Zapatka · National Cancer Institute13 papers (2013–2023) · 11 papers (2014–2023) · 11 papers (2014–2023)Dolors Colomer · China United Network Communications Group (China)11 papers (2018–2022)Tobias Roider · University Hospital Heidelberg10 papers (2019–2024)Ralph Schulz · Heidelberg University9 papers (2016–2021)Claudia Dürr · German Cancer Research Center9 papers (2012–2019)Verena Kalter · Heidelberg University9 papers (2014–2021)Elı́as Campo · Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer8 papers (2017–2022)Franziska Haderk · Boehringer Ingelheim (Germany)7 papers (2013–2017)John G. Gribben · University of Pennsylvania7 papers (2014–2018)Murat Iskar · German Cancer Research Center6 papers (2016–2021)